Paris, France, France · Est. 1929 · 5,800 employees
Ipsen is a global biopharmaceutical company focused on innovative medicines in oncology, neuroscience, and rare diseases.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
By Phase
9 drugs in development
By Therapeutic Area
top 4
R&D Momentum
67/100
Pipeline Velocity
42/100
Trial Completion Rate
77/100
Pipeline Concentration
27/100
Pipeline Freshness
77/100
Strategic Signals
Activity
Last 14 days
A Phase II, Randomized, Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics (PK) of Maintenance Cabozantinib (XL184) Plus Best Supportive Care (BSC) Versus BSC in Children, Adolescents and Young Adults (AYA) With Unresectable Residual Osteosarcoma Either at Diagnosis or at First Relapse After Standard Treatment
Registry to Document Treatment Effectiveness, Safety, Including Prospective Long-term Outcomes in Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay)
A Phase III Randomised, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm Study to Evaluate the Efficacy and Safety of Elafibranor 80 mg on Long-Term Clinical Outcomes in Adult Participants With Primary Biliary Cholangitis (PBC)
Analysis of the Effect of Odevixibat (A4250) Versus External Controls on Clinical Outcomes in Patients With PFIC (Odevixibat Versus External Control [OvEC]-PFIC)
Registry to Document Treatment Effectiveness, Safety, Including Prospective Long-term Outcomes in Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay).
A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC).
An International Observational Registry Study to Further Describe Long-term Safety and Effectiveness of Palovarotene in Patients With Fibrodysplasia Ossificans Progressiva (FOP)
A Phase III, Open-label, Single Arm Study to Investigate the Efficacy and Safety of Elafibranor 80 mg in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
Odevixibat Pregnancy and Lactation Surveillance Program: A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Individuals Exposed to Odevixibat During Pregnancy and/or Lactation
Prospective Registry-Based Study Evaluating the Effectiveness and Safety of Odevixibat in Participants With Alagille Syndrome (ALGS)
A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis
Details
Company Overview
$13.5B
Mkt Cap
$3.6B
Revenue
—
Cash
Therapeutic Focus
Pipeline
Regulatory
INCRELEX — INCRELEX
Application BLA021839 (BLA)
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Dysport — DYSPORT
Application BLA125274
Bylvay — BYLVAY
Application NDA215498 (NDA)
Dysport — DYSPORT
Application BLA125274
Sohonos — SOHONOS
Application NDA215559 (NDA)
Dysport — DYSPORT
Application BLA125274
Iqirvo — IQIRVO
Application NDA218860 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)